235 related articles for article (PubMed ID: 16551740)
41. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome.
Puurunen J; Piltonen T; Jaakkola P; Ruokonen A; Morin-Papunen L; Tapanainen JS
J Clin Endocrinol Metab; 2009 Jun; 94(6):1973-8. PubMed ID: 19318449
[TBL] [Abstract][Full Text] [Related]
42. Upregulation of adipose 11-beta-hydroxysteroid dehydrogenase type 1 expression in ovariectomized rats is due to obesity rather than lack of estrogen.
Paulsen SK; Nielsen MP; Richelsen B; Bruun JM; Flyvbjerg A; Pedersen SB
Obesity (Silver Spring); 2008 Apr; 16(4):731-5. PubMed ID: 18379559
[TBL] [Abstract][Full Text] [Related]
43. Role of ovary and adrenal glands in hyperandrogenemia in patients with polycystic ovary syndrome.
Kamel N; Tonyukuk V; Emral R; Corapçioğlu D; Baştemir M; Güllü S
Exp Clin Endocrinol Diabetes; 2005 Feb; 113(2):115-21. PubMed ID: 15772904
[TBL] [Abstract][Full Text] [Related]
44. Association studies between microsatellite markers within the gene encoding human 11beta-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism.
Draper N; Echwald SM; Lavery GG; Walker EA; Fraser R; Davies E; Sørensen TI; Astrup A; Adamski J; Hewison M; Connell JM; Pedersen O; Stewart PM
J Clin Endocrinol Metab; 2002 Nov; 87(11):4984-90. PubMed ID: 12414862
[TBL] [Abstract][Full Text] [Related]
45. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
[TBL] [Abstract][Full Text] [Related]
46. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome.
Zhou R; Bird IM; Dumesic DA; Abbott DH
J Clin Endocrinol Metab; 2005 Dec; 90(12):6630-7. PubMed ID: 16174719
[TBL] [Abstract][Full Text] [Related]
47. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.
Cooper MS; Stewart PM
J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912
[TBL] [Abstract][Full Text] [Related]
48. The role of adrenal hyperandrogenism, insulin resistance, and obesity in the pathogenesis of polycystic ovarian syndrome.
Rittmaster RS; Deshwal N; Lehman L
J Clin Endocrinol Metab; 1993 May; 76(5):1295-300. PubMed ID: 8388405
[TBL] [Abstract][Full Text] [Related]
49. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
[TBL] [Abstract][Full Text] [Related]
50. Overexpression of hepatic 5α-reductase and 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients.
Baudrand R; Domínguez JM; Carvajal CA; Riquelme A; Campino C; Macchiavello S; Bozinovic M; Morales M; Pizarro M; Solis N; Escalona A; Boza C; Arrese M; Fardella CE
Metabolism; 2011 Dec; 60(12):1775-80. PubMed ID: 21704348
[TBL] [Abstract][Full Text] [Related]
51. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome.
González F; Rote NS; Minium J; Kirwan JP
J Clin Endocrinol Metab; 2006 Jan; 91(1):336-40. PubMed ID: 16249279
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of the pituitary-adrenal axis in hyperandrogenic women with polycystic ovary syndrome.
Luboshitzky R; Ishai A; Shen-Or Z; Herer P
Neuro Endocrinol Lett; 2003; 24(3-4):249-54. PubMed ID: 14523365
[TBL] [Abstract][Full Text] [Related]
53. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
[TBL] [Abstract][Full Text] [Related]
54. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
Kowalska I; Straczkowski M; Nikolajuk A; Adamska A; Karczewska-Kupczewska M; Otziomek E; Wolczynski S; Gorska M
Hum Reprod; 2007 Jul; 22(7):1824-9. PubMed ID: 17582143
[TBL] [Abstract][Full Text] [Related]
55. Association between 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population.
Dujic T; Bego T; Mlinar B; Semiz S; Malenica M; Prnjavorac B; Ostanek B; Marc J; Causevic A
Biochem Med (Zagreb); 2012; 22(1):76-85. PubMed ID: 22384521
[TBL] [Abstract][Full Text] [Related]
56. The effect of common genetic variation in 11β-hydroxysteroid dehydrogenase type 1 on hypothalamic-pituitary-adrenal axis activity and incident depression.
Dekker MJ; Tiemeier H; Luijendijk HJ; Kuningas M; Hofman A; de Jong FH; Stewart PM; Koper JW; Lamberts SW
J Clin Endocrinol Metab; 2012 Feb; 97(2):E233-7. PubMed ID: 22112815
[TBL] [Abstract][Full Text] [Related]
57. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome.
Toscani MK; Mario FM; Radavelli-Bagatini S; Spritzer PM
Nutr Res; 2011 Feb; 31(2):97-103. PubMed ID: 21419313
[TBL] [Abstract][Full Text] [Related]
58. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
59. Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome.
Wehr E; Schweighofer N; Möller R; Giuliani A; Pieber TR; Obermayer-Pietsch B
Metabolism; 2010 Apr; 59(4):575-80. PubMed ID: 19913856
[TBL] [Abstract][Full Text] [Related]
60. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
